Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Insitro Gains $25 Million From BMS Milestones in ALS Genetic Target Discovery
Details : The companies signed a collaboration agreement to discover new therapies for the treatment of myotrophic lateral sclerosis .
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $50.0 million
December 18, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Study Phase : Discovery Platform
Sponsor : Eli Lilly
Deal Size : Undisclosed
Deal Type : Collaboration
Lilly, insitro Enter Strategic Agreements for Metabolic Diseases
Details : insitro and Lilly will collaborate to discover and develop an antibody for a third novel target for metabolic disease and will work together on the early preclinical development activities.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 10, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Endocrinology
Highest Development Status : Discovery Platform
Sponsor : Eli Lilly
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Insitro will apply its proprietary platform, the insitro Human (ISH) platform, to create induced pluripotent stem cell (iPSC) derived disease models for ALS and FTD. BMS will be responsible for clinical development and regulatory submissions and commerci...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $50.0 million
October 28, 2020